Seagen's share is currently hovering around $175, having gained around 20% since speculation of a Merck bid started in earnest in the middle of June, giving it a market capitalisation of around ...

There has been another twist in the road for the ongoing legal battle between Seagen and Daiichi Sankyo over patent rights for antibody-drug conjugate (ADC) Enhertu. The US Patent and Trademark ...